{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:37:28Z","timestamp":1773286648200,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.4065\/mcp.2010.0470","type":"journal-article","created":{"date-parts":[[2010,11,24]],"date-time":"2010-11-24T23:42:15Z","timestamp":1290642135000},"page":"S38-S49","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S","title":["Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus"],"prefix":"10.4065","volume":"85","author":[{"given":"Jeff","family":"Unger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/mcp.2010.0470_bib1","series-title":"Diabetes Management in Primary Care","first-page":"1","article-title":"Introduction","author":"Unger","year":"2007"},{"issue":"3","key":"10.4065\/mcp.2010.0470_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1557-0843(09)80029-8","article-title":"Appropriate, timely, and rational treatment of type 2 diabetes mellitus: meeting the challenges of primary care","volume":"4","author":"Unger","year":"2009","journal-title":"Insulin"},{"key":"10.4065\/mcp.2010.0470_bib3","series-title":"National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007","author":"Centers for Disease Control and Prevention (CDC)","year":"2008"},{"issue":"19","key":"10.4065\/mcp.2010.0470_bib4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/archinte.168.19.2088","article-title":"National trends in treatment of type 2 diabetes mellitus, 1994-2007","volume":"168","author":"Alexander","year":"2008","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"10.4065\/mcp.2010.0470_bib6","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1152\/ajpendo.00545.2003","article-title":"Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans","volume":"287","author":"Holst","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"8","key":"10.4065\/mcp.2010.0470_bib7","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.86.8.3717","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.4065\/mcp.2010.0470_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"issue":"2","key":"10.4065\/mcp.2010.0470_bib9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF02576216","article-title":"Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas","volume":"193","author":"Goke","year":"1993","journal-title":"Res Exp Med (Berl)"},{"issue":"6","key":"10.4065\/mcp.2010.0470_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1043-2760(99)00157-5","article-title":"Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential","volume":"10","author":"Holst","year":"1999","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1210\/jc.81.1.327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-0495(96)90192-4","article-title":"Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake","volume":"45","author":"Young","year":"1996","journal-title":"Metabolism"},{"issue":"6560","key":"10.4065\/mcp.2010.0470_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.4065\/mcp.2010.0470_bib14","series-title":"Diabetes Management in Primary Care","first-page":"618","article-title":"Amylin, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase IV (DPP-IV) inhibitors as novel treatments for diabetes","author":"Unger","year":"2007"},{"key":"10.4065\/mcp.2010.0470_bib15","series-title":"Byetta (exenatide BID) [package insert]","year":"2009"},{"issue":"4","key":"10.4065\/mcp.2010.0470_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib17","first-page":"S1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus","volume":"13","author":"American Association of Clinical Endocrinologists Diabetes Mellitus Clinical Practice Guidelines Task Force","year":"2007","journal-title":"Endocr Pract"},{"issue":"1-2","key":"10.4065\/mcp.2010.0470_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.mce.2008.08.012","article-title":"The incretin system and its role in type 2 diabetes mellitus","volume":"297","author":"Holst","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"10.4065\/mcp.2010.0470_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-004-1342-6","article-title":"Incretins, insulin secretion and type 2 diabetes mellitus","volume":"47","author":"Vilsb\u00f8ll","year":"2004","journal-title":"Diabetologia"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"issue":"8","key":"10.4065\/mcp.2010.0470_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"issue":"suppl 3","key":"10.4065\/mcp.2010.0470_bib22","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.2337\/diabetes.53.suppl_3.S190","article-title":"Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes","volume":"53","author":"Nauck","year":"2004","journal-title":"Diabetes"},{"issue":"9548","key":"10.4065\/mcp.2010.0470_bib23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.4065\/mcp.2010.0470_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/157339908784220705","article-title":"Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors","volume":"4","author":"Stonehouse","year":"2008","journal-title":"Curr Diabetes Rev"},{"issue":"14","key":"10.4065\/mcp.2010.0470_bib25","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2165\/11201060-000000000-00000","article-title":"Liraglutide: a review of its use in type 2 diabetes mellitus","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"issue":"suppl","key":"10.4065\/mcp.2010.0470_bib26","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.2337\/dc09-S315","article-title":"Incretin-based therapies: viewpoints on the way to consensus","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"6","key":"10.4065\/mcp.2010.0470_bib27","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.2337\/dc07-0233","article-title":"Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications","volume":"30","author":"Ahren","year":"2007","journal-title":"Diabetes Care"},{"issue":"12(suppl)","key":"10.4065\/mcp.2010.0470_bib28","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4065\/mcp.2010.0469","article-title":"Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors","volume":"85","author":"Davidson","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.4065\/mcp.2010.0470_bib29","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","article-title":"Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study","volume":"24","author":"DeFronzo","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.4065\/mcp.2010.0470_bib30","author":"Bergenstal"},{"issue":"9724","key":"10.4065\/mcp.2010.0470_bib31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","article-title":"Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycemic control with metformin: a 26-week, randomized, parallel-group, open-label trial [published correction appears in Lancet. 2010; 376(9737):234]","volume":"375","author":"Pratley","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.4065\/mcp.2010.0470_bib32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"issue":"11","key":"10.4065\/mcp.2010.0470_bib33","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4065\/mcp.2010.0470_bib34","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"issue":"5","key":"10.4065\/mcp.2010.0470_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079907X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.4065\/mcp.2010.0470_bib37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"10.4065\/mcp.2010.0470_bib38","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clin Ther"},{"issue":"8","key":"10.4065\/mcp.2010.0470_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.4065\/mcp.2010.0470_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"issue":"9645","key":"10.4065\/mcp.2010.0470_bib41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib42","first-page":"A43","article-title":"Exenatide once-weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment [abstract 165-OR]","volume":"58","author":"Bergenstal","year":"2009","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib43","first-page":"A42","article-title":"Exenatide once weekly treatment effects sustained glycemic control and weight loss over 2 years [abstract 159-OR]","volume":"58","author":"Kim","year":"2009","journal-title":"Diabetes"},{"issue":"3","key":"10.4065\/mcp.2010.0470_bib44","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once daily human GLP-1 analogue, added to sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4065\/mcp.2010.0470_bib46","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide Effect and Action in Diabetes 5 (LEAD-5) MET+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 MET+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"9662","key":"10.4065\/mcp.2010.0470_bib47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.4065\/mcp.2010.0470_bib48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/17446651.4.2.119","article-title":"Liraglutide Effect and Action in Diabetes (LEAD) trial","volume":"4","author":"Madsbad","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"9683","key":"10.4065\/mcp.2010.0470_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.4065\/mcp.2010.0470_bib50","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/diacare.27.6.1335","article-title":"Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagons-like peptide 1 analog liraglutide (NN211)","volume":"27","author":"Madsbad","year":"2004","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib51","first-page":"A42","article-title":"Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1C, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3-Mono 2-year results [abstract 162-OR]","volume":"58","author":"Garber","year":"2009","journal-title":"Diabetes"},{"issue":"12","key":"10.4065\/mcp.2010.0470_bib52","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4065\/mcp.2010.0470_bib53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1463-1326.2006.00704.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial","volume":"9","author":"Nauck","year":"2007","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.4065\/mcp.2010.0470_bib54","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"issue":"9","key":"10.4065\/mcp.2010.0470_bib55","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.4065\/mcp.2010.0470_bib56","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1185\/03007990903178735","article-title":"Effect of saxagliptin monotherapy in treatment-na\u00efve patients with type 2 diabetes","volume":"25","author":"Rosenstock","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.4065\/mcp.2010.0470_bib57","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1185\/03007990903156111","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"25","author":"Pratley","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1742-1241.2008.01933.x","article-title":"Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study","volume":"63","author":"Nauck","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.4065\/mcp.2010.0470_bib59","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1464-5491.2008.02391.x","article-title":"Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial","volume":"25","author":"Pan","year":"2008","journal-title":"Diabet Med"},{"issue":"3","key":"10.4065\/mcp.2010.0470_bib60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1055\/s-2007-970422","article-title":"Vildagliptin in drugna\u00efve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study","volume":"39","author":"Dejager","year":"2007","journal-title":"Horm Metab Res"},{"issue":"5","key":"10.4065\/mcp.2010.0470_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MAJ.0b013e31818eb721","article-title":"Impact of sitagliptin on markers of beta-cell function: a meta-analysis","volume":"337","author":"Riche","year":"2009","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib62","first-page":"37","article-title":"Primary care physicians' perceptions of diabetes management: a balancing act","volume":"48","author":"Helseth","year":"1999","journal-title":"J Fam Pract"},{"issue":"3","key":"10.4065\/mcp.2010.0470_bib63","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabres.2006.09.037","article-title":"Awareness of pathophysiological concepts of type 2 diabetes: a survey in 847 physicians","volume":"76","author":"Busse","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.4065\/mcp.2010.0470_bib64","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1463-1326.2008.01018.x","article-title":"Exenatide: a review from pharmacology to clinical practice","volume":"11","author":"Gentilella","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.4065\/mcp.2010.0470_bib65","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1530\/EJE-09-0101","article-title":"Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"160","author":"Monami","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.4065\/mcp.2010.0470_bib66","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"95","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"10.4065\/mcp.2010.0470_bib67","series-title":"Victoza (liraglutide) [package insert]","year":"2010"},{"issue":"6","key":"10.4065\/mcp.2010.0470_bib68","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc09-2260","article-title":"Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4065\/mcp.2010.0470_bib69","author":"Buse"},{"issue":"4","key":"10.4065\/mcp.2010.0470_bib70","doi-asserted-by":"crossref","first-page":"374.e9","DOI":"10.1016\/j.amjmed.2009.07.017","article-title":"Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications","volume":"123","author":"Bergenstal","year":"2010","journal-title":"Am J Med"},{"issue":"5","key":"10.4065\/mcp.2010.0470_bib71","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib72","first-page":"A41","article-title":"Incidence of acute pancreatitis in exenatide initiators compared to other antidiabetic drug initiators: a retrospective, cohort study [abstract 158-OR]","volume":"58","author":"Bloomgren","year":"2009","journal-title":"Diabetes"},{"issue":"4","key":"10.4065\/mcp.2010.0470_bib73","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","article-title":"Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide","volume":"25","author":"Dore","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib74","first-page":"A96","article-title":"Cardiovascular safety of exenatide bid: an integrated analysis from long-term clinical trials in subjects with type 2 diabetes [abstract 366-OR]","volume":"58","author":"Shen","year":"2009","journal-title":"Diabetes"},{"issue":"1","key":"10.4065\/mcp.2010.0470_bib75","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11906-009-0005-x","article-title":"The role of incretins in cardiovascular control","volume":"11","author":"Mafong","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"10.4065\/mcp.2010.0470_bib76","series-title":"Sitagliptin (marketed as Januvia and Janumet)\u2014acute pancreatitis","author":"US Food and Drug Administration (FDA)","year":"2009"},{"issue":"suppl 1","key":"10.4065\/mcp.2010.0470_bib77","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc10-S011","article-title":"Standards of medical care in diabetes\u20142010","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4065\/mcp.2010.0470_bib78","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4158\/EP.15.6.540","article-title":"Statement by an American Association of Clinical Endocrinologists\/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control","volume":"15","author":"Rodbard","year":"2009","journal-title":"Endocr Pract"},{"issue":"12(suppl)","key":"10.4065\/mcp.2010.0470_bib79","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.4065\/mcp.2010.0468","article-title":"Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia","volume":"85","author":"Schwartz","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/mcp.2010.0470_bib80","series-title":"Diabetes Management in Primary Care","first-page":"405","article-title":"Lifestyle interventions for patients with diabetes","author":"Unger","year":"2007"},{"issue":"9 (suppl)","key":"10.4065\/mcp.2010.0470_bib81","first-page":"S26","article-title":"How to implement incretin therapy","volume":"57","author":"Cobble","year":"2008","journal-title":"J Fam Pract"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611603790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T11:53:59Z","timestamp":1544097239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611603790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0025619611603790"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2010.0470","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}